Dilaudid-Hp generics — when can they launch?
Dilaudid-Hp (Hydromorphone Hydrochloride) · Fresenius Kabi · 14 active US patents · 0 expired
Where Dilaudid-Hp sits in the generic timeline
Mid-term cliff: earliest active US patent for Dilaudid-Hp expires in 2032 (~6 years). Generic developers typically begin ANDA bioequivalence studies 3-4 years ahead of this date. Paragraph IV filings + Hatch-Waxman 30-month stays may shift the effective entry by another 18-36 months.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Formulation — 14 patents
Sample patent estate
Showing 6 of 14 active US patents. View full estate on the Dilaudid-Hp drug page →
-
This patent protects an assembly of an injection device with a heat-shrinkable film covering parts of the device and an adaptor to maintain the adaptor in place.USPTO title: Drug container
-
This patent protects an assembly of an injection device with a heat-shrinkable film covering parts of the device and an adaptor to maintain the adaptor in place.USPTO title: Drug container
-
This patent protects an assembly of an injection device with a heat-shrinkable film covering parts of the device and an adaptor to maintain the adaptor in place.USPTO title: Drug container
-
This patent protects an assembly of an injection device with a heat-shrinkable film covering parts of the device and an adaptor to maintain the adaptor in place.USPTO title: Drug container
-
This patent protects an assembly of an injection device with a heat-shrinkable film covering parts of the device and an adaptor to maintain the adaptor in place.USPTO title: Drug container
-
This patent protects an assembly of an injection device with a heat-shrinkable film covering parts of the device and an adaptor to maintain the adaptor in place.USPTO title: Drug container
Sources
- FDA Orange Book — patents listed against Dilaudid-Hp (NDA filed 1984)
- Dilaudid-Hp drug profile — full patent estate, indications, clinical trials, pricing
- Fresenius Kabi patent portfolio
- Patent cliff 2032 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Dilaudid-Hp — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →